Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Karyopharm Therapeutics (KPTI) Consolidated Net Income (2016 - 2025)

Historic Consolidated Net Income for Karyopharm Therapeutics (KPTI) over the last 14 years, with Q4 2025 value amounting to -$102.2 million.

  • Karyopharm Therapeutics' Consolidated Net Income fell 23116.66% to -$102.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$196.0 million, marking a year-over-year decrease of 15625.34%. This contributed to the annual value of -$196.0 million for FY2025, which is 15625.34% down from last year.
  • As of Q4 2025, Karyopharm Therapeutics' Consolidated Net Income stood at -$102.2 million, which was down 23116.66% from -$33.1 million recorded in Q3 2025.
  • In the past 5 years, Karyopharm Therapeutics' Consolidated Net Income ranged from a high of $38.7 million in Q4 2021 and a low of -$102.2 million during Q4 2025
  • For the 5-year period, Karyopharm Therapeutics' Consolidated Net Income averaged around -$35.3 million, with its median value being -$36.8 million (2022).
  • Its Consolidated Net Income has fluctuated over the past 5 years, first skyrocketed by 18909.97% in 2021, then tumbled by 25657.36% in 2025.
  • Karyopharm Therapeutics' Consolidated Net Income (Quarter) stood at $38.7 million in 2021, then tumbled by 201.92% to -$39.4 million in 2022, then fell by 6.73% to -$42.1 million in 2023, then rose by 26.67% to -$30.9 million in 2024, then plummeted by 231.17% to -$102.2 million in 2025.
  • Its last three reported values are -$102.2 million in Q4 2025, -$33.1 million for Q3 2025, and -$37.3 million during Q2 2025.